UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 621

Sortiert nach

Safety and Immunogenicity of 26-Valent Group A Streptococcus Vaccine in Healthy Adult Volunteers

Clinical infectious diseases, 2005-10, Vol.41 (8), p.1114-1122

2005

Link zum Volltext

Verfügbarkeit prüfen

Immunogenicity of a 26-Valent Group A Streptococcal Vaccine

Infection and Immunity, 2002-04, Vol.70 (4), p.2171-2177

2002

Link zum Volltext

Verfügbarkeit prüfen

The Effect of Feeding a Dry Enzyme Mixture with Fibrolytic Activity on the Performance of Lactating Cows and Digestibility of a Diet for Sheep

Journal of dairy science, 2007-10, Vol.90 (10), p.4724-4729

2007

Link zum Volltext

Verfügbarkeit prüfen

Cancer-associated MUC1 mucin inhibits human T-cell proliferation, which is reversible by IL-2

Nature medicine, 1998-01, Vol.4 (1), p.43-49

1998

Link zum Volltext

Verfügbarkeit prüfen

Safety and immunogenicity of a recombinant multivalent group a streptococcal vaccine in healthy adults: phase 1 trial

JAMA : the journal of the American Medical Association, 2004-08, Vol.292 (6), p.709

2004

Link zum Volltext

Verfügbarkeit prüfen

Intranasal Immunization with Multivalent Group A Streptococcal Vaccines Protects Mice against Intranasal Challenge Infections

Infection and Immunity, 2004-05, Vol.72 (5), p.2507-2512

2004

Link zum Volltext

Verfügbarkeit prüfen

The breast mucin MUC1 as a novel adhesion ligand for endothelial intercellular adhesion molecule 1 in breast cancer

Cancer research (Chicago, Ill.), 1996-09, Vol.56 (18), p.4244-4249

1996

Link zum Volltext

Verfügbarkeit prüfen

Clinical outcome of breast and ovarian cancer patients treated with high-dose chemotherapy, autologous stem cell rescue and THERATOPE® STn-KLH cancer vaccine

Bone marrow transplantation (Basingstoke), 2000-06, Vol.25 (12), p.1233-1241

2000

Link zum Volltext

Verfügbarkeit prüfen

Liposomal Formulations of Synthetic MUC1 Peptides: Effects of Encapsulation versus Surface Display of Peptides on Immune Responses

Bioconjugate chemistry, 1998-07, Vol.9 (4), p.451-458

1998

Link zum Volltext

Verfügbarkeit prüfen

Evidence of a cellular immune response against sialyl-Tn in breast and ovarian cancer patients after high-dose chemotherapy, stem cell rescue, and immunization with Theratope STn-KLH cancer vaccine

Journal of immunotherapy, 1999-01, Vol.22 (1), p.54-66

1999

Link zum Volltext

Verfügbarkeit prüfen

Antibodies against mucin-associated sialyl-Tn epitopes correlate with survival of metastatic adenocarcinoma patients undergoing active specific immunotherapy with synthetic STn vaccine

Journal of immunotherapy with emphasis on tumor immunology, 1996-01, Vol.19 (1), p.59

1996

Link zum Volltext

Verfügbarkeit prüfen

Enhancing the effect of THERATOPE STn-KLH cancer vaccine in patients with metastatic breast cancer by pretreatment with low-dose intravenous cyclophosphamide

Journal of immunotherapy with emphasis on tumor immunology, 1996-07, Vol.19 (4), p.309

1996

Link zum Volltext

Verfügbarkeit prüfen

Anti‐MUC1 class I restricted CTLs in metastatic breast cancer patients immunized with a synthetic MUC1 peptide

International journal of cancer, 1998-06, Vol.76 (6), p.817-823

1998

Link zum Volltext

Verfügbarkeit prüfen

Immunogenicity and antitumor activity of a liposomal MUC1 peptide‐based vaccine

International journal of cancer, 1998-01, Vol.75 (2), p.295-302

1998

Link zum Volltext

Verfügbarkeit prüfen

Vaccines prepared with sialyl-Tn and sialyl-Tn trimers using the 4-(4-maleimidomethyl)cyclohexane-1-carboxyl hydrazide linker group result in optimal antibody titers against ovine submaxillary mucin and sialyl-Tn-positive tumor cells

Cancer Immunology, Immunotherapy, 1999-04, Vol.48 (1), p.1-8

1999

Link zum Volltext

Verfügbarkeit prüfen

Rapid induction of primary human CD4+ and CD8+ T cell responses against cancer-associated MUC1 peptide epitopes

International immunology, 1998-12, Vol.10 (12), p.1907-1916

1998

Link zum Volltext

Verfügbarkeit prüfen

Does pregnancy immunize against breast cancer ?

Cancer research (Chicago, Ill.), 1995-06, Vol.55 (11), p.2257-2261

1995

Link zum Volltext

Verfügbarkeit prüfen

DNA replication in the hyperthermophilic archaeon Sulfolobus solfataricus

Biochemical Society transactions, 2003-06, Vol.31 (Pt 3), p.674

2003

Link zum Volltext

Verfügbarkeit prüfen

Pre-immunotherapy serum CA27.29 (MUC-1) mucin level and CD69+ lymphocytes correlate with effects of Theratope® sialyl-Tn-KLH cancer vaccine in active specific immunotherapy

Cancer Immunology, Immunotherapy, 1996-06, Vol.42 (5), p.303-309

1996

Link zum Volltext

Verfügbarkeit prüfen

Specificities of anti-sialyl-Tn and anti-Tn monoclonal antibodies generated using novel clustered synthetic glycopeptide epitopes

Glycoconjugate journal, 1997-08, Vol.14 (5), p.549-560

1997

Link zum Volltext

Verfügbarkeit prüfen

In vitro induction of MUC-1 peptide-specific type 1 T lymphocyte and cytotoxic T lymphocyte responses from healthy multiparous donors

The Journal of immunology (1950), 1996-09, Vol.157 (5), p.2089

1996

Link zum Volltext

Verfügbarkeit prüfen

The anti-MUC1 monoclonal antibody BCP8 can be used to isolate and identify putative major histocompatibility complex class I associated amino acid sequences

Cancer research (Chicago, Ill.), 1998-11, Vol.58 (22), p.5151-5156

1998

Link zum Volltext

Verfügbarkeit prüfen

CD69+ and HLA‐DR+ activation antigens on peripheral blood lymphocyte populations in metastatic breast and ovarian cancer patients: Correlations with survival following active specific immunotherapy

International journal of cancer, 1995-05, Vol.61 (4), p.470-474

1995

Link zum Volltext

Verfügbarkeit prüfen

Sex Differences in Responses to Probability Markers in Advertising Claims

Journal of advertising, 2006-07, Vol.35 (2), p.7-16

2006

Link zum Volltext

Verfügbarkeit prüfen

Prognostic significance of preimmunotherapy serum CA27.29 (MUC-1) mucin level after active specific immunotherapy of metastatic adenocarcinoma patients

Journal of immunotherapy (1997), 1997-01, Vol.20 (1), p.70

1997

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 621

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(384)
Mit Volltextzugriff
(463)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(228)
Life Sciences & Biomedicine
(112)
Physical Sciences
(88)
Humans
(86)
Physics
(58)
Female
(56)
Animals
(42)
Science & Technology - Other Topics
(33)
Biological And Medical Sciences
(32)
Multidisciplinary Sciences
(30)
Exact Sciences And Technology
(28)
Technology
(27)
Physics, Atomic, Molecular & Chemical
(25)
Immunology
(24)
Male
(24)
Social Sciences
(23)
Biochemistry & Molecular Biology
(22)
Medical Sciences
(22)
Geology & The Lithosphere
(21)
Mining Technology & Engineering
(21)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Safety and Immunogenicity of 26-Valent Group A Streptococcus Vaccine in Healthy Adult Volunteers

Immunogenicity of a 26-Valent Group A Streptococcal Vaccine

The Effect of Feeding a Dry Enzyme Mixture with Fibrolytic Activity on the Performance of Lactating Cows and Digestibility of a Diet for Sheep

Cancer-associated MUC1 mucin inhibits human T-cell proliferation, which is reversible by IL-2

Safety and immunogenicity of a recombinant multivalent group a streptococcal vaccine in healthy adults: phase 1 trial

Intranasal Immunization with Multivalent Group A Streptococcal Vaccines Protects Mice against Intranasal Challenge Infections

The breast mucin MUC1 as a novel adhesion ligand for endothelial intercellular adhesion molecule 1 in breast cancer

Clinical outcome of breast and ovarian cancer patients treated with high-dose chemotherapy, autologous stem cell rescue and THERATOPE® STn-KLH cancer vaccine

Liposomal Formulations of Synthetic MUC1 Peptides: Effects of Encapsulation versus Surface Display of Peptides on Immune Responses

Evidence of a cellular immune response against sialyl-Tn in breast and ovarian cancer patients after high-dose chemotherapy, stem cell rescue, and immunization with Theratope STn-KLH cancer vaccine

Antibodies against mucin-associated sialyl-Tn epitopes correlate with survival of metastatic adenocarcinoma patients undergoing active specific immunotherapy with synthetic STn vaccine

Enhancing the effect of THERATOPE STn-KLH cancer vaccine in patients with metastatic breast cancer by pretreatment with low-dose intravenous cyclophosphamide

Anti‐MUC1 class I restricted CTLs in metastatic breast cancer patients immunized with a synthetic MUC1 peptide

Immunogenicity and antitumor activity of a liposomal MUC1 peptide‐based vaccine

Vaccines prepared with sialyl-Tn and sialyl-Tn trimers using the 4-(4-maleimidomethyl)cyclohexane-1-carboxyl hydrazide linker group result in optimal antibody titers against ovine submaxillary mucin and sialyl-Tn-positive tumor cells

Rapid induction of primary human CD4+ and CD8+ T cell responses against cancer-associated MUC1 peptide epitopes

Does pregnancy immunize against breast cancer ?

DNA replication in the hyperthermophilic archaeon Sulfolobus solfataricus

Pre-immunotherapy serum CA27.29 (MUC-1) mucin level and CD69+ lymphocytes correlate with effects of Theratope® sialyl-Tn-KLH cancer vaccine in active specific immunotherapy

Specificities of anti-sialyl-Tn and anti-Tn monoclonal antibodies generated using novel clustered synthetic glycopeptide epitopes

In vitro induction of MUC-1 peptide-specific type 1 T lymphocyte and cytotoxic T lymphocyte responses from healthy multiparous donors

The anti-MUC1 monoclonal antibody BCP8 can be used to isolate and identify putative major histocompatibility complex class I associated amino acid sequences

CD69+ and HLA‐DR+ activation antigens on peripheral blood lymphocyte populations in metastatic breast and ovarian cancer patients: Correlations with survival following active specific immunotherapy

Sex Differences in Responses to Probability Markers in Advertising Claims

Prognostic significance of preimmunotherapy serum CA27.29 (MUC-1) mucin level after active specific immunotherapy of metastatic adenocarcinoma patients

Suchergebnisse filtern